Status:
UNKNOWN
Apoptosis and Hepatitis B: The Role of Apoptosis in Patients Who Are HBeAg Negative
Lead Sponsor:
University Health Network, Toronto
Conditions:
Hepatitis B
Eligibility:
All Genders
18-90 years
Brief Summary
A large number hepatitis B surface antigen positive individuals are HBeAg negative with normal liver tests. Historically, such patients were thought to have suppressed viral replication and were consi...
Detailed Description
Through a retrospective chart review, patients with HBsAg who are HBeAg negative, have normal ALT, and HBV DNA \>10,000 copies/mL and who have or who are about to undergo liver biopsy will be identifi...
Eligibility Criteria
Inclusion
- HBsAg positive.
- Stable HBeAg status for at least one year prior to biopsy.
- Normal ALT levels (defined as \<1.5 x the upper limit of normal) for at least 90 days prior to biopsy.
- HBV DNA ≥10,000 copies/mL by PCR measured within 90 days of liver biopsy.
- patients attending Liver Clinic at Toronto Western Hospital, Toronto, ON, Canada
Exclusion
- Coinfection with viral hepatitis A, C or D.
- Coinfection with HIV.
- Presence of Hepatoma.
- Known presence of other malignancy.
- Previous antiviral treatment.
Key Trial Info
Start Date :
July 1 2005
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00152880
Start Date
July 1 2005
Last Update
December 1 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liver Clinic, Toronto Western Hospital, UHN.
Toronto, Ontario, Canada, M5T 2S8